CSF2, colony stimulating factor 2, 1437

N. diseases: 1028; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.370 Biomarker group BEFREE A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas. 27581603 2016
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.370 AlteredExpression group BEFREE Only in LC-positive carcinomas did epithelial cells close to lymphoid aggregates display small amounts of GM-CSF and TNF alpha mRNA expression. 7635448 1995
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.370 Therapeutic group CTD_human Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A. 11605069 2001
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.370 Biomarker group BEFREE Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. 15613691 2005
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.370 AlteredExpression group BEFREE Our data show that the LNCaP cells express functional GM-CSF receptors and that prostatic carcinomas have prominent GM-CSF receptor expression. 9446667 1998
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.370 Biomarker group BEFREE Magmas, a conserved mammalian protein essential for eukaryotic development, is overexpressed in prostate carcinomas and cells exposed to granulocyte-macrophage colony-stimulating factor (GM-CSF). 20053669 2010
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.370 Biomarker group BEFREE (c) Some, but not all, lung carcinomas produced this cytokine, and a close correlation was found between the production of GM-CSF and the number of CD1a+ LC infiltrating these tumors. 7679411 1993
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.370 Biomarker group BEFREE Recent research found abnormal expression of the c-fms oncogene, which encodes the macrophage colony-stimulating factor receptor (CSF-1R), in several human carcinomas including hepatocellular carcinoma (HCC). 14969845 2004
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.360 Therapeutic group CTD_human Combination therapy with GM-CSF and IL-12 represents a promising immunotherapy strategy for treating orthotopic, widespread liver tumors. 17326190 2007
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.360 Biomarker group BEFREE The results showed that combined gene transfer of p21WAF-1 and GM-CSF could inhibit the growth of pre-established tumor more effectively and prolong the survival time of hepatoma-bearing mice more significantly than the transfer of a single gene. 11916239 2002
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.360 GeneticVariation group BEFREE To test whether antitumor activity could be increased by combining the above two mechanisms, this study examined the therapeutic effect of combination gene therapy using a murine granulocyte-macrophage colony-stimulating factor (mGM-CSF) gene and a human endostatin (hED) gene on a rat orthotopic liver tumor model. 12731087 2003
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.360 AlteredExpression group BEFREE Therefore, these results suggest that combining expression of GM-CSF and B70 may enhance NK-mediated cytotoxicity, and then induce the antitumor immunity in hepatoma transplanted into nude mice. 11295284 2001
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.360 AlteredExpression group BEFREE The distant bystander effect was associated with a strong induction of GMCSF and IL-12 expression in the untreated TK-negative liver tumors. 11880183 2002
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.360 Biomarker group BEFREE Combination therapy with GM-CSF and IL-12 represents a promising immunotherapy strategy for treating orthotopic, widespread liver tumors. 17326190 2007
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.360 Biomarker group BEFREE The results demonstrated that combined administration of p21(WAF-1) and GM-CSF could remarkably inhibit the growth of subcutaneously transplanted hepatoma Hepa cells, and significantly increase the survival rate of tumor-bearing mice. 12833133 2003
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.350 Biomarker group BEFREE First, immunotherapy with an allogeneic, HER2-positive, GM-CSF-secreting breast tumor vaccine alone or with CY and DOX is safe and induces HER2-specific immunity in patients with metastatic breast cancer. 19805669 2009
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.350 Therapeutic group CTD_human Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. 11325840 2001
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.350 Biomarker group BEFREE Thus, we explored the potential immune-modulating effects of sorafenib in a murine HER-2-(neu) overexpressing breast tumor model alone and in combination with a HER-2 targeted granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting vaccine (3T3neuGM). 28282575 2017
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.350 Biomarker group BEFREE We have previously reported that, in a phase I pilot study (ClinicalTrials.gov NCT00095862), a subject with stage IV breast cancer experienced substantial regression of breast, lung, and brain lesions following inoculation with clinical formulations of SV-BR-1-GM, a GM-CSF-secreting breast tumor cell line. 29867922 2018
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.350 Biomarker group BEFREE Immunization with two recombinant Bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice. 20127358 2010
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.350 Biomarker group BEFREE Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. 12748184 2003
CUI: C1261473
Disease: Sarcoma
Sarcoma
0.330 Biomarker group BEFREE The efficacy of Ad5/3-D24-GMCSF was evaluated on a panel of soft-tissue sarcoma (STS) cell lines and in two animal models. 24374597 2014
CUI: C1261473
Disease: Sarcoma
Sarcoma
0.330 Therapeutic group CTD_human The effectiveness of combined chemoimmunotherapy with ifosfamide derivative CBM-4A and granulocyte-macrophage colony-stimulating factor (GM-CSF) was investigated in two experimental tumor models, 3MC-induced MHC class I+ sarcoma Mc12 and HPV16 E6/E7 oncogene-induced MHC class I- carcinoma MK16, transplanted in syngeneic mice. 11605069 2001
CUI: C1261473
Disease: Sarcoma
Sarcoma
0.330 Biomarker group BEFREE The v-fms oncogene of the McDonough strain of feline sarcoma virus (SM-FeSV) encodes a plasma-membrane-associated tyrosine kinase (gp140v-fms) which is closely related, both structurally and functionally, to the c-fms-specified receptor for the macrophage colony stimulating factor (CSF-1). 2171188 1990
CUI: C1261473
Disease: Sarcoma
Sarcoma
0.330 GeneticVariation group BEFREE As described in this protocol, fresh human sarcoma and melanoma specimens can be transfected with the GM-CSF DNA-coated gold particles with subsequent production of biologically active GM-CSF protein. 9143914 1997